NXI-201 / NEX-I - LARVOL DELTA

Nexi to Present at BioEurope 2025, Introducing 'NXI-201' and More [Google translation] (HIT News) - "In this presentation, Nex-I introduced its proprietary immuno-oncology drug development platform technology that transforms refractory (cold tumors) into responsive (hot tumors) tumors, as well as the progress of non-clinical trials for its main pipeline, 'NXI-201.' NXI-201 is a follow-up pipeline to 'NXI-101,' the technology of which was transferred to Ono Pharmaceutical Co., Ltd. of Japan in 2024, and is preparing to submit an IND for clinical trials within the year....At this event, the company also plans to partner on the development of ADCs using 'NXI-201' and cell surface immuno-oncology refractory target antibodies."

IND • Solid Tumor